Is Sihuan Pharmaceutical Holdings Group (HKG:460) Weighed On By Its Debt Load?

Simply Wall St17:50 ET

Sihuan Pharm (00460.HK) plans to spin off Xuanzhu Biotech and list it on the main board of the Hong Kong Stock Exchange, as well as further acquire approximately 3.6177% equity of Xuanzhu Biotech.

Galunhui, November 12 | Sihuan Pharm (00460.HK) announced that the company proposed to spin off Xuanzhu Biotech's shares and list on the Main Board of the Stock Exchange, and the company has obtained the Stock Exchange's approval for the proposed spin-off of Xuanzhu Biotech in accordance with Application Guidance Note 15 of the Listing Rules. The board of directors believes that the proposed spin-off will help Xuanzhu Biotech further establish itself as an independent innovative drug research and industrialization platform company, enabling direct access to debt and equity capital markets, thereby enhancing Xuanzhu Biotech's financial flexibility and strengthening its ability to raise external funds to support its rapid business growth and industrial development, while the company can also

Gelonghui FinanceNov 12 09:12 ET

Express News | Sihuan Pharma - Unit to Further Acquire 3.6177% Stake in Xuanzhu Biopharmaceutical for RMB308 Mln

ReutersNov 12 09:09 ET

Express News | Sihuan Pharma - Proposed Spin-off of Xuanzhu Biopharm and Listing on Main Board of Stock Exchange

ReutersNov 12 09:08 ET

The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.

On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.

cls.cnNov 12 02:44 ET

Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.

①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?

cls.cnNov 11 21:59 ET